Opinion|Videos|April 14, 2025
The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) (Lp[a]) testing, exploring the varying recommendations from organizations such as the American Association of Clinical Endocrinologists, the American Heart Association, and the National Lipid Association (NLA), and how these align with recent guidance from Europe and Canada.
Advertisement
Video content above is prompted by the following:
- How do guideline recommendations factor into formulary decisions about preventive measures like Lp(a) testing?
- In the introduction, I mentioned that there are several national and international guidelines offering slightly different recommendations about when Lp(a) should be measured. Among these are statements from the American Association of Clinical Endocrinologists and American College of Endocrinology, the American Heart Association, and the American College of Cardiology from 2022 or earlier, which recommend Lp(a) measurement in patients with a family history of atherosclerotic cardiovascular disease and/or elevated Lp(a) levels. However, in 2024, the NLA recommended that Lp(a) be measured in all adults. How does this recommendation align with recent guidance from Europe and Canada?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5